title: Physiological phenotype and vulnerability in Parkinson's disease.
abstract: This review will focus on the principles underlying the hypothesis that neuronal physiological phenotype-how a neuron generates and regulates action potentials-makes a significant contribution to its vulnerability in Parkinson's disease (PD) and aging. A cornerstone of this hypothesis is that the maintenance of ionic gradients underlying excitability can pose a significant energetic burden for neurons, particularly those that have sustained residence times at depolarized membrane potentials, broad action potentials, prominent Ca(2+) entry, and modest intrinsic Ca(2+) buffering capacity. This energetic burden is shouldered in neurons primarily by mitochondria, the sites of cellular respiration. Mitochondrial respiration increases the production of damaging superoxide and other reactive oxygen species (ROS) that have widely been postulated to contribute to cellular aging and PD. Many of the genetic mutations and toxins associated with PD compromise mitochondrial function, providing a mechanistic linkage between known risk factors and cellular physiology that could explain the pattern of pathology in PD. Because much of the mitochondrial burden created by this at-risk phenotype is created by Ca(2+) entry through L-type voltage-dependent channels for which there are antagonists approved for human use, a neuroprotective strategy to reduce this burden is feasible.
authors: Department of Physiology, Northwestern University, Chicago, Illinois, USA. j-surmeier@northwestern.edu
authors: D James
authors: DJ
authors: Surmeier
authors: Jaime N
authors: JN
authors: Guzman
authors: Javier
authors: J
authors: Sanchez
authors: Paul T
authors: PT
authors: Schumacker
mesh_terms: D000200:Action Potentials; D000375:Aging / Q000502:physiology; D000818:Animals; D020746:Calcium Channels, L-Type / Q000502:physiology; D004272:DNA, Mitochondrial; D004095:Dihydropyridines / Q000627:therapeutic use; D004198:Disease Susceptibility / Q000503:physiopathology*; D004298:Dopamine / Q000096:biosynthesis; D004734:Energy Metabolism; D006801:Humans; D007477:Ions; D008928:Mitochondria / Q000235:genetics / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism / Q000502:physiology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D010641:Phenotype; D017382:Reactive Oxygen Species / Q000378:metabolism; D017384:Sequence Deletion; D013378:Substantia Nigra / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D020746:Calcium Channels, L-Type; D004272:DNA, Mitochondrial; D004095:Dihydropyridines; D007477:Ions; D017382:Reactive Oxygen Species; D004298:Dopamine